Can Fite BioPharma Ltd (CANF)

[midastouch017]

BioLine RX (BLRX)

https://finance.yahoo.com/news/7-high-potential-penny-stocks-175605720.html

BioLine RX (NASDAQ:BLRX) just announced the FDA acceptance of its APHEXDA (motixafortide) new drug application (NDA). This is for stem cell mobilization for autologous transplantation in multiple myeloma patients. There’s a PDUFA target date of Sept. 9.

Even better, BLRX just announced the publication of data from its GENESIS Phase 3 clinical trial in the Nature Medicine journal, which “evaluated the safety and efficacy of the company’s lead investigational candidate motixafortide plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF for the mobilization of hematopoietic stem cells in patients with multiple myeloma prior to autologous stem cell transplantation (ASCT).”

These data highlighted the potential of motixafortide plus G-CSF, if approved, to enhance the treatment options for clinicians and patients with multiple myeloma undergoing ASCT.